Biosimilar Firms Main Beneficiaries Of Korea R&D Cost Accounting Changes?
Executive Summary
Helped by new guidelines, South Korean pharma and biotech firms now have clearer standards related to the reflection of R&D costs in their accounting books, with some pointing out that biosimilar companies may be the biggest beneficiaries.